• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Biodexa Pharmaceuticals plc - American Depositary Shares (NQ:BDRX)

    3.415 +0.065 (+1.94%)
    Streaming Delayed Price Updated: 3:10 PM EDT, Apr 8, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Biodexa Pharmaceuticals plc - American Depositary Shares

    News headline image
    Microcap Madness: DOSE, GV, GPUS, ADMQ, BDRX, AMLM Finals to Watch
    Via AB Newswire
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer
    Via ACCESS Newswire
    News headline image
    Surging Stocks: AMCI, BDRX, SURG, VMAR, TOON More Stocks Inside
    Via AB Newswire
    News headline image
    Myseum (NASDAQ: MYSE) Realizes $6.8M in Asset Sale – Watch AMCI, ARTV, QIPT, SURG Today!
    Via AB Newswire
    News headline image
    Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer
    Via ACCESSWIRE
    News headline image
    Biodexa Looks To Prevent Or Delay The Worst Outcomes For Adolescents And Young Adults With Devastating Precancerous Condition
    Via ACCESSWIRE
    News headline image
    Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers
    Via ACCESSWIRE
    News headline image
    ENDRA Life Sciences (NASDAQ: NDRA) Advances TAEUS® Liver Imaging, Strengthens Capital Efficiency; WVE, TWG, BDRX, FULC Also Active
    Via AB Newswire
    News headline image
    Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled
    Via ACCESS Newswire
    News headline image
    How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market
    Via ACCESS Newswire
    News headline image
    Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study
    Via ACCESS Newswire
    News headline image
    Biodexa Takes Aim At Type 1 Diabetes With Innovative Drug Candidate Tolimidone
    Via ACCESSWIRE
    News headline image
    Biodexa Pharmaceuticals PLC Announces Exercise of Pre-Funded Warrants & Issue of Equity
    Via ACCESSWIRE
    News headline image
    Biodexa Pharmaceuticals PLC Announces Exercise of Pre-Funded Warrants & Issue of Equity
    Via ACCESSWIRE
    News headline image
    With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter
    Via ACCESS Newswire
    News headline image
    Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status
    Via ACCESS Newswire
    News headline image
    Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic
    Via ACCESSWIRE
    News headline image
    BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    News headline image
    Biodexa Pharmaceuticals PLC Announces Exercise of Pre-Funded Warrants & Issue of Equity
    Via ACCESSWIRE
    News headline image
    Biodexa Pharmaceuticals PLC Announces Exercise of Pre-Funded Warrants & Issue of Equity
    Via ACCESSWIRE
    News headline image
    Biodexa Pharmaceuticals PLC Announces Exercise of Pre-Funded Warrants & Issue of Equity
    Via ACCESSWIRE
    News headline image
    BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    News headline image
    Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa in Treatment Of Precancerous Polyps in the GI Tract - Now 12-Month Data
    Via ACCESSWIRE
    News headline image
    Promising Phase 2 Results For Biodexa's eRapa(TM) Indicates Hope for FAP Patients Who Otherwise Have a 100% Lifetime Risk of Colorectal Cancer
    Via ACCESSWIRE
    News headline image
    Biodexa Pharmaceuticals PLC Announces Issue of Pre-Funded Warrants
    Via ACCESSWIRE
    News headline image
    Biodexa Pharmaceuticals PLC Announces Exercise of Warrants and Issue of Equity
    Via ACCESSWIRE
    News headline image
    Biodexa Pharmaceuticals PLC Announces Exercise of Warrants and Issue of Equity
    Via ACCESSWIRE
    News headline image
    Biodexa Pharmaceuticals PLC Announces Exercise of Warrants and Issue of Equity
    Via ACCESSWIRE
    Biotech Market Update: Global Pharmaceuticals Market Expected to Reach $1.5 Trillion by Year’s End
    EQNX::TICKER_START (NYSE:PTN),(NASDAQ:CRDF),(NASDAQ:BDRX),(NASDAQ:DRUG),(NYSE:LLY) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.